Through our twelve recently launched National Centers of Excellence across North America and Canada dedicated to sharing clinical excellence, we continue to develop and expand the knowledge and patient access to our market-leading technologies, such as the Vbeam Prima, Gentle Pro Series, Profound and Picoway. "In addition to our heavy investment in developing groundbreaking technologies, the core of our market approach centers around building clinical trust with our customers and using our technology to change lives. Those two patents protecting our Profound RF based Microneedle product were not involved in the Sublative litigation," says Geoffrey Crouse, CEO of Syneron Candela. Dieter Manstein, at Massachusetts General Hospital, is the inventor on the two patents being asserted in the fractional RF micro-needle litigation filed with the International Trade Commission. Syneron Candela intends to vigorously pursue its pending appeal concerning its Sublative patents. On the same day that judgment was entered, the company filed an appeal with the Court of Appeals for the Federal Circuit. Unrelated to the above mentioned fractional RF micro-needling case, a patent infringement lawsuit concerning Sublative technology and involving different patents initiated in January 2016 by Syneron Candela's former owners against InMode Ltd and Invasix in the US District Court for the Central District of California recently resulted in the asserted claims of those unrelated patents being held invalid over prior art. of all fractional RF micro-needle products and is currently scheduled for trial on May 6, 2019. The lawsuit filed with the ITC seeks to block importation into the U.S. and Perigee Medical LLC Infini by Lutronic, Corp. Legend Pro by Lumenis Ltd and Pollogen Ltd 3DEEP by EndyMed Medical Ltd. Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics, LLC Fractora by Invasix Ltd., Invasix, Inc. The accused infringing products include Secret RF by ilooda Co., Ltd. International Trade Commission in Washington, D.C. and in federal district court. In April 2018, defending its Profound RF based Microneedle product, Syneron Candela filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. 7, 2018 /PRNewswire/ - Syneron Medical Ltd and its subsidiary Candela Corporation (collectively, Syneron Candela), a leading global aesthetic device company announced updates today to several patent infringement lawsuits.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |